Improving Liquid Biopsy Concordance Using Novel Reference Materials

Profiling cell-free DNA (cfDNA) in a blood sample for the presence of circulating tumor DNA (ctDNA) has enabled minimally invasive post-resection surveillance of tumor recurrence and shows promise for early detection of cancer. The relatively limited quantity of cfDNA in a given blood draw limits the ability to retest a sample plus the low overall abundance of ctDNA fraction leads to unique quality control challenges within the molecular oncology diagnostics space.

The use of high-quality reference materials can assist in development, validation of analytic sensitivity, cross-site comparisons, and general performance monitoring of liquid biopsy assays. In this workshop LGC will present new developments in standalone reference materials as well as an AccuGenomics partnership using spike-in standards to improve concordance and robustness of liquid biopsies.

Russell Garlick will lead the panel discussion. Cecilia Yeung MD, Fred Hutch Cancer Center, will present data that are part of the FNIH AML MRD study, Yves Konigshofer will present data from the ctDNA spike-in reference materials and Andrew Anfora will present a customer led study showcasing the newly launched Seraseq ctDNA v4.